Immuron Limited American Depositary Shares (IMRN)
Stock · NASDAQ · Health Care
$0.982as of 10/16/2026
Price chart
Active signals
IMRN Signal Track Record
How signals performed across all stocks →What IMRN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 27 | -8.6% | 22% | September 4, 2026 |
| Bollinger Band Breakdown | 25 | +0.9% | 52% | December 10, 2025 |
| Volume Spike | 24 | -2.5% | 29% | September 4, 2026 |
| 200-Day Moving Average TouchActive now | 14 | -2.9% | 43% | August 5, 2026 |
| Any 20-session window (baseline) | -1.5% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMRN
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers'…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 7
- Website
- www.immuron.com.au
Fundamentals
- 1-day range
- $0.99$1.04
- Market cap
- $8.88M
- P/E (trailing)
- —
- P/E (forward)
- -103.00
- EPS (trailing)
- $-0.01
- Dividend yield
- —
- Beta
- -0.76
- Avg. volume
- 2.10M
Immuron Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- IMRNImmuron Limited American Depositary Shares$0.982▼ 4.66%Market cap $8.88MP/E —$0.026$0.098
- LEXXLexaria Bioscience Corp. Common Stock$2.86▼ 4.35%Market cap $8.82MP/E —$2.43$21.6
- ASBPAspire Biopharma Holdings Inc. Common Stock$8.78▲ 1.62%Market cap $9.14MP/E —$3.31$562.8
- XCURExicure Inc. Common Stock$1.12▲ 0.00%Market cap $8.60MP/E —$0.936$9.48
- QNRXQuoin Pharmaceuticals Ltd. American Depositary Shares$3.9▼ 3.23%Market cap $9.18MP/E —$3.25$23.5
- KAPAKairos Pharma Ltd. Common Stock$0.601▼ 10.43%Market cap $8.35MP/E —$0.7108$9.17
- GDTCCytoMed Therapeutics Limited Ordinary Shares$0.88▲ 1.15%Market cap $9.50MP/E —$0.6801$3.68
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMRN Immuron Limited American Depositary Shares | $8.88M | — | $0.982 | ▼ 4.66% | $0.026$0.098 |
| LEXX Lexaria Bioscience Corp. Common Stock | $8.82M | — | $2.86 | ▼ 4.35% | $2.43$21.6 |
| ASBP Aspire Biopharma Holdings Inc. Common Stock | $9.14M | — | $8.78 | ▲ 1.62% | $3.31$562.8 |
| XCUR Exicure Inc. Common Stock | $8.60M | — | $1.12 | ▲ 0.00% | $0.936$9.48 |
| QNRX Quoin Pharmaceuticals Ltd. American Depositary Shares | $9.18M | — | $3.9 | ▼ 3.23% | $3.25$23.5 |
| KAPA Kairos Pharma Ltd. Common Stock | $8.35M | — | $0.601 | ▼ 10.43% | $0.7108$9.17 |
| GDTC CytoMed Therapeutics Limited Ordinary Shares | $9.50M | — | $0.88 | ▲ 1.15% | $0.6801$3.68 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebobenzinga · 10/13/2026
- Immuron Limited (IMRN) Presents at Coffee Microcaps Conference 2026 - SlideshowSeekingAlpha · 9/22/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 84.9K
- Total value held
- $65.7K
- Institutional holders
- 7
- Unknown30.6K
- Unknown17.4K
- Unknown13.8K
- Unknown10.9K
- Unknown7.4K
- Unknown4.6K
- Unknown225
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Immuron Reports 50% Drop in ETEC Adverse Events from Phase 2 Trial
Immuron has released data from a phase 2 study of its once‑daily oral drug Travelan. The publication in Scientific Reports reports a 50% reduction in ETEC‑related adverse events compared with placebo, a statistically significant finding. This result adds evidence to the company’s clinical pipeline and may influence how the market views its product development prospects.
Immuron Reports 50% Drop in ETEC Adverse Events from Phase 2 Trial. Immuron has released data from a phase 2 study of its once‑daily oral drug Travelan. The publication in Scientific Reports reports a 50% reduction in ETEC‑related adverse events compared with placebo, a statistically significant finding. This result adds evidence to the company’s clinical pipeline and may influence how the market views its product development prospects.